Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtre
1.
Chinese Journal of Hematology ; (12): 370-375, 2022.
Article Dans Chinois | WPRIM | ID: wpr-929570

Résumé

Objective: To investigate the prognostic significance of interferon regulatory factor 9 (IRF9) expression and identify its role as a potential therapeutic target in acute promyelocytic leukemia (APL) . Methods: The gene expression profile and survival data applied in the bioinformatic analysis were obtained from The Cancer Genome Atlas and Beat acute myeloid leukemia (AML) cohorts. A dox-induced lentiviral system was used to induce the expression of PML-RARα (PR) in U937 cells, and the expression level of IRF9 in U937 cells treated with or without ATRA was examined. We then induced the expression of IRF9 in NB4, a promyelocytic leukemia cell line. In vitro studies focused on leukemic phenotypes triggered by IRF9 expression. Results: ①Bioinformatic analysis of the public database demonstrated the lowest expression of IRF9 in APL among all subtypes of AML, with lower expression associated with worse prognosis. ②We successfully established a PR-expression-inducible U937 cell line and found that IRF9 was downregulated by the PR fusion gene in APL, with undetectable expression in NB4 promyelocytic cells. ③An IRF9-inducible NB4 cell line was successfully established. The inducible expression of IRF9 promoted the differentiation of NB4 cells and had a synergistic effect with lower doses of ATRA. In addition, the inducible expression of IRF9 significantly reduced the colony formation capacity of NB4 cells. Conclusion: In this study, we found that the inducible expression of PR downregulates IRF9 and can be reversed by ATRA, suggesting a specific regulatory relationship between IRF9 and the PR fusion gene. The induction of IRF9 expression in NB4 cells can promote cell differentiation as well as reduce the colony forming ability of leukemia cells, implying an anti-leukemia effect for IRF9, which lays a biological foundation for IRF9 as a potential target for the treatment of APL.


Sujets)
Humains , Différenciation cellulaire , Sous-unité gamma du complexe ISGF3/métabolisme , Leucémie aigüe myéloïde/traitement médicamenteux , Leucémie aiguë promyélocytaire/génétique , Protéines de fusion oncogènes/métabolisme , Phénotype , Trétinoïne/usage thérapeutique , Cellules U937
2.
Neurol India ; 2007 Jan-Mar; 55(1): 64-6
Article Dans Anglais | IMSEAR | ID: sea-120797

Résumé

The authors describe an extremely rare case with malignant peripheral nerve sheath tumor (MPNST) with focal epithelioid differentiation presenting as an intraosseous lesion of the spine. A 75-year-old woman presented with progressive paraplegia caused by epidural mass arising from the posterior element of the T7 vertebra. At surgery, the lesion was noted to originate from the T7 vertebra and separate from the dura and spinal nerve roots. The patient died of tumor metastases to the lungs six months after the initial presentation. Histological diagnosis was MPNST. However, the tumor also contained cystic structures lined by epithelioid cells, requiring differentiation from synovial sarcoma. From the histological and immunohistochemical features, as well as the absence of SYT-SSX fusion gene expression, the diagnosis of MPNST with focal epithelioid differentiation was made. This is the first case report of intraosseous MPNST of the spine with a peculiar biphasic appearance.


Sujets)
Sujet âgé , Cellules épithélioïdes/métabolisme , Femelle , Humains , Imagerie par résonance magnétique , Tumeurs des gaines nerveuses/anatomopathologie , Protéines de fusion oncogènes/métabolisme , Tumeurs du système nerveux périphérique/anatomopathologie , Rachis/anatomopathologie , Vertèbres thoraciques
3.
Indian J Cancer ; 2003 Oct-Dec; 40(4): 135-9
Article Dans Anglais | IMSEAR | ID: sea-49360

Résumé

BACKGROUND: The technique of Fluorescence In-Situ Hybridization (FISH), a hybrid of cytogenetics and molecular biology has increased the resolution and application of cytogenetics in various neoplastic processes. In various types of leukemias, primary investigation by conventional cytogenetic [CC] technique followed by FISH has increased our understanding of the abnormal clonal formation involving different gene region. AIMS: Present study is aimed to use different kinds of in-house FISH probes in various hematological malignancies and its correlation with conventional cytogenetic finding. MATERIAL AND METHODS: Cytogenetic study was carried out in 360 patients either from peripheral blood or from bone marrow cells suspected for various types of leukemias. Four of 360 cases were further selected for FISH study by using different types of in-house probes, such as BAC [Bacterial Artificial Chromosome], PAC [Phague Artificial Chromosome], alphoid, PCP [Partial Chromosome Paint] and WCP [Whole Chromosome paint]. RESULTS: The results confirmed breakpoints of inversion 16 and del 16 in case 2 and 3 respectively. Whereas, case 1 did not confirm the cytogenetic findings of t(15;17) by PML/RARa fusion signals as multiple cell lines were involved in the patients. PCP and WCP were helpful in the identification of the marker chromosome in case 1. Telomeric and centromeric probes confirmed the cytogenetic findings of t(5;7) in case 4. CONCLUSION: We observe from this study that, in addition to the conventional cytogenetic study, FISH study provide further confirmation of chromosomal rearrangements. This facilitates our understanding of the neoplastic process more precisely for the better prognostication of the patient.


Sujets)
Cellules de la moelle osseuse/anatomopathologie , Aberrations des chromosomes , Délétion de segment de chromosome , Peinture chromosomique , Chromosomes artificiels de bactérie/génétique , Chromosomes humains de la paire 15/génétique , Chromosomes humains de la paire 16/génétique , Chromosomes humains de la paire 17/génétique , Analyse cytogénétique , Sondes d'ADN , Humains , Hybridation fluorescente in situ/méthodes , Leucémie aigüe myélomonocytaire/génétique , Leucémie aiguë promyélocytaire/génétique , Syndromes myélodysplasiques/génétique , Protéines de fusion oncogènes/métabolisme , Translocation génétique
SÉLECTION CITATIONS
Détails de la recherche